Kuwabara Masanari
Division of Public Health, Center for Community Medicine, Jichi Medical University, Tochigi, Japan.
Division of Cardiovascular Medicine, Department of Medicine, Jichi Medical University, Tochigi, Japan.
Hypertens Res. 2025 Mar;48(3):1192-1194. doi: 10.1038/s41440-024-02015-9. Epub 2024 Nov 14.
Cancer and cardiovascular disease (CVD) are the leading causes of death in Japan, with an increasingly recognized interrelationship. Both diseases share numerous risk factors and pathophysiological mechanisms, suggesting a bidirectional influence on onset and progression. Recent studies reveal that cancer survivors face elevated CVD risks, particularly shortly after diagnosis, while CVD may predispose individuals to cancer. Cancer treatments, including chemotherapy, can lead to cardiotoxicity and increased CVD complications. A study by Suzuki et al. demonstrates that individuals with hypertension and a history of cancer, especially those treated with chemotherapy, have a higher risk of developing CVD events. Despite limitations in study design and data specificity, these findings highlight the importance of long-term cardiovascular monitoring in cancer survivors. As cardio-oncology evolves, developing evidence-based guidelines and fostering collaboration between oncologists and cardiologists is crucial for optimizing patient care and outcomes in both cancer and CVD management.
癌症和心血管疾病（CVD）是日本的主要死因，二者之间的相互关系日益受到认可。这两种疾病有许多共同的风险因素和病理生理机制，表明它们在发病和进展方面存在双向影响。最近的研究表明，癌症幸存者面临着更高的心血管疾病风险，尤其是在诊断后不久，而心血管疾病可能使个体易患癌症。包括化疗在内的癌症治疗可导致心脏毒性和心血管疾病并发症增加。铃木等人的一项研究表明，患有高血压且有癌症病史的个体，尤其是接受过化疗的个体，发生心血管疾病事件的风险更高。尽管研究设计和数据特异性存在局限性，但这些发现凸显了对癌症幸存者进行长期心血管监测的重要性。随着心脏肿瘤学的发展，制定基于证据的指南并促进肿瘤学家和心脏病学家之间的合作对于优化癌症和心血管疾病管理中的患者护理及治疗效果至关重要。
